Work

Real-world evidence of fruquintinib (Fruq) efficacy after regorafenib (Rego) and trifluridine–tipiracil (TAS-102) in refractory metastatic colorectal cancer (mCRC).

Year: 2025

Type: article

Study design: Observational Study

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.e23317

Authors: Oluseyi Abidoye, Anina Peersen, Jennah Bauernfeind, Mohamad Bassam Sonbol, Christina Wu, Tanios S. Bekaii-Saab, Fang-Shu Ou, Daniel H. Ahn

Institutions: Mayo Clinic in Arizona, Mayo Clinic Hospital, Mayo Clinic Comprehensive Cancer Center (Arizona), Mayo Clinic

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410814490

FWCI:

Cites:

Cited by:

Related to: 10